Month: April 2020

Communiqué de presse22 avril 2020 – N° 8Renouvellements P&C d’avril 2020SCOR Global P&C renouvelle avec succèsson portefeuille au 1er avril 2020A l’issue des renouvellements du 1er avril 2020, SCOR Global P&C augmente son volume de primes brutes en réassurance de 5,7%1, à taux de change constants2, pour atteindre EUR 504 millions, tout en bénéficiant d’une amélioration générale des conditions de marché comme en témoigne une augmentation tarifaire moyenne de 6,6%1.La région Asie-Pacifique représente 57%1 des renouvellements du 1er avril 2020, avec deux marchés principaux :Au Japon, SCOR Global P&C enregistre une croissance de 5,4%, bénéficiant de hausses tarifaires et de cessions rentables supplémentaires. En outre, SCOR Global P&C a redéployé une partie de ses capacités vers des tranches de risque de plus...

PR N°C2955C Geneva, April 22, 2020 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, reported an update on its 2020 Annual General Meeting of Shareholders (the “2020 AGM”).Taking into account the increasing global societal and economic turmoil caused by the COVID-19 outbreak, ST’s Supervisory Board is now proposing a decrease in the 2019 dividend from US$0.24 to US$0.168 per share, with the authorization to consider, during September 2020, to increase such dividend up to a maximum of US$0.24 per share.The updated dividend resolution will be proposed at the 2020 AGM which is now postponed to June 17, 2020.The main resolutions to be submitted for adoption at the rescheduled 2020 AGM include:The adoption of the Company’s statutory annual accounts...

PR N°C2955C Genève, le 22 avril 2020 – STMicroelectronics (NYSE : STM), un leader mondial dont les clients couvrent toute la gamme des applications électroniques, informe d’une mise à jour concernant son Assemblée Générale Annuelle des Actionnaires 2020 (AGA 2020).Prenant en compte la croissance des bouleversements économiques et sociétaux dans le monde liés à l’épidémie de COVID-19, le Conseil de Surveillance de ST propose désormais une réduction du montant du dividende 2019 de 0,24 US$ à 0,168 US$ par action, avec l’autorisation d’envisager, au cours du mois de septembre 2020, de l’augmenter jusqu’à un maximum de 0,24 US$ par action.La mise à jour de la résolution concernant le dividende sera proposée à l’AGM 2020 qui est désormais reprogrammée au 17 juin 2020.Les principales résolutions proposées pour approbation lors de l’AGM...

If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults with r/r DLBCLThe Regenerative Medicine Advanced Therapy (RMAT) designation reflects the unmet need for patients with r/r follicular lymphomaUS regulatory filing for Kymriah in r/r follicular lymphoma anticipated in 2021 Basel, April 22, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah® (tisagenlecleucel), for an investigational new indication to treat patients with relapsed or refractory (r/r) follicular lymphoma (FL). Kymriah, which is designed to be a one-time treatment, is the first-ever FDA-approved CAR-T cell therapy. The potential...

The Annual Report 2019 for Belships ASA is enclosed. The Annual Report is also available on our website www.belships.comThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentBelships Annual Report 2019

SANTA CLARA, Calif., April 22, 2020 (GLOBE NEWSWIRE) — Inphi Corporation (NYSE: IPHI) today announced the pricing of $440.0 million aggregate principal amount of 0.75% convertible senior notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, The principal amount of the offering was increased from the previously announced offering size of $330.0 million. Inphi granted the initial purchasers of the notes a 13-day option to purchase up to an additional $66.0 million aggregate principal amount of notes on the same terms and conditions. The sale of the notes is scheduled to close on April 24, 2020, subject to satisfaction of customary closing conditions.Inphi...

MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the decision to host its 2020 Ordinary General Meeting remotely on May 5, 2020 and to postpone its Extraordinary General Meeting to June 8, 2020 from May 5, 2020.Materials for both the Ordinary and Extraordinary Shareholders’ Meetings can be found on the Investors section of the Company’s website under “Shareholder Meetings”.Ordinary Shareholders’ Meeting of May 5, 2020In view of the current exceptional circumstances linked to the COVID-19 pandemic and in accordance with Royal Decree No. 4 of April 9, 2020, the Board of Directors of Celyad have decided to prohibit the physical presence...

Basel, 22 April 2020Group sales increase 2% in Swiss francs and 7% at constant exchange rates, driven by new products, more than compensating for impact of competition from biosimilarsPharmaceuticals Division sales up 7%, led by Tecentriq, Hemlibra, Ocrevus and PerjetaDiagnostics Division sales grow 5%, with molecular testing as main contributorImportant approvals in the first quarter:in China: Tecentriq for first-line combination therapy of extensive-stage small cell lung cancerin the US: CINtec Plus Cytology test and cobas HPV test for use on cobas 6800/8800 Systems for cervical cancer screeningin the EU: Polivy in combination with bendamustine and MabThera/Rituxan, for the treatment of adult patients with a special form of B-cell lymphomain the EU: Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for adults with previously untreated...

Bâle, le 22 avril 2020Le chiffre d’affaires consolidé augmente de 2% en francs suisses et de 7% à taux de change constants, sous l’impulsion des nouveaux produits, dont les ventes ont plus que compensé l’impact de la concurrence des biosimilaires.Le chiffre d’affaires de la division Pharma augmente de 7%, porté par Tecentriq, Hemlibra, Ocrevus et Perjeta.Le chiffre d’affaires de la division Diagnostics progresse de 5%, les tests moléculaires étant le principal contributeur de la croissance.Homologations importantes au premier trimestre:en Chine: Tecentriq en association thérapeutique pour le traitement de première ligne du cancer du poumon à petites cellules de stade étenduaux Etats-Unis: les tests CINtec Plus Cytology et cobas HPV, à utiliser sur les systèmes cobas 6800/8800, pour le dépistage du cancer du col de l’utérusdans l’UE: Polivy...

Basel, 22. April 2020Konzernverkäufe steigen um 2% in Schweizer Franken und 7% zu konstanten Wechselkursen, Hauptwachstumsträger sind neue Produkte, deren Verkäufe den Umsatzrückgang infolge des Wettbewerbs mit Biosimilars deutlich übersteigenVerkäufe der Division Pharma erhöhen sich um 7%, Hauptwachstumsträger sind Tecentriq, Hemlibra, Ocrevus und PerjetaVerkäufe der Division Diagnostics wachsen um 5%, vor allem dank der MolekulardiagnostikWichtige Zulassungen im ersten Quartal:in China: Tecentriq im Rahmen einer Kombinationstherapie zur Erstlinienbehandlung von kleinzelligem Lungenkrebs in fortgeschrittenem Stadiumin den USA: CINtec Plus Zytologie-Test und cobas HPV Test für die cobas 6800/8800 Systeme für das Gebärmutterhalskrebs-Screeningin der EU: Polivy in Kombination mit Bendamustine und MabThera/Rituxan für die Behandlung Erwachsener...